Literature DB >> 1659439

Comparative effects of the antimycotic drugs ketoconazole, fluconazole, itraconazole and terbinafine on the metabolism of cyclosporin by human liver microsomes.

D J Back1, J F Tjia.   

Abstract

Four antimycotic drugs, the azoles ketoconazole, itraconazole and fluconazole, and the allylamine terbinafine have been studied for their effect on the metabolism of cyclosporin by human liver microsomes (n = 3) in vitro. Ketoconazole caused marked inhibition of cyclosporin hydroxylase (to metabolites M17 and M1) with IC50 and Ki values of 0.24 +/- 0.01 and 0.022 +/- 0.004 microM, respectively. Based on IC50 values, itraconazole was ten times less potent (IC50 value of 2.2 +/- 0.2 microM) and both fluconazole and terbinafine had values above 100 microM. Ki values for itraconazole and fluconazole were 0.7 +/- 0.2 and 40 +/- 5.6 microM, respectively. No kinetic parameters were calculated for terbinafine because of the lack of inhibitory effects. Based on these data, ketoconazole is confirmed as being a potent inhibitor of cyclosporin metabolism and this has clinical relevance. Although inhibition by fluconazole was much less than that by itraconazole at equimolar concentrations, it should be noted that in patients plasma concentrations of fluconazole are much greater than those of itraconazole. Clinical interactions of cyclosporin with both fluconazole and itraconazole have been reported. In contrast to the azoles, terbinafine does not have the same potential for interaction.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1659439      PMCID: PMC1368642          DOI: 10.1111/j.1365-2125.1991.tb03963.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  25 in total

1.  Concomitant cyclosporin and ketoconazole.

Authors:  F J Frey
Journal:  Lancet       Date:  1990-01-13       Impact factor: 79.321

Review 2.  Fluconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses.

Authors:  S M Grant; S P Clissold
Journal:  Drugs       Date:  1990-06       Impact factor: 9.546

3.  Cyclosporine A: a clinical evaluation of drug interactions.

Authors:  I Cockburn
Journal:  Transplant Proc       Date:  1986-12       Impact factor: 1.066

4.  Ketoconazole, cyclosporin metabolism, and renal transplantation.

Authors:  R M Ferguson; D E Sutherland; R L Simmons; J S Najarian
Journal:  Lancet       Date:  1982-10-16       Impact factor: 79.321

5.  Time course of cyclosporin/itraconazole interaction.

Authors:  D Trenk; W Brett; E Jähnchen; D Birnbaum
Journal:  Lancet       Date:  1987-12-05       Impact factor: 79.321

6.  Interaction of cyclosporin and itraconazole.

Authors:  J T Kwan; P J Foxall; D G Davidson; M R Bending; A J Eisinger
Journal:  Lancet       Date:  1987-08-01       Impact factor: 79.321

7.  The interaction of representative members from two classes of antimycotics--the azoles and the allylamines--with cytochromes P-450 in steroidogenic tissues and liver.

Authors:  I Schuster
Journal:  Xenobiotica       Date:  1985-06       Impact factor: 1.908

8.  The metabolism of 17 alpha-ethinyloestradiol by human liver microsomes: formation of catechol and chemically reactive metabolites.

Authors:  H S Purba; J L Maggs; M L Orme; D J Back; B K Park
Journal:  Br J Clin Pharmacol       Date:  1987-04       Impact factor: 4.335

9.  Drug interactions with fluconazole.

Authors:  J D Lazar; K D Wilner
Journal:  Rev Infect Dis       Date:  1990 Mar-Apr

10.  Cyclosporin toxicity at therapeutic blood levels and cytochrome P-450 IIIA.

Authors:  M R Lucey; J C Kolars; R M Merion; D A Campbell; M Aldrich; P B Watkins
Journal:  Lancet       Date:  1990-01-06       Impact factor: 79.321

View more
  27 in total

1.  Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.

Authors:  P Damkier; L L Hansen; K Brosen
Journal:  Br J Clin Pharmacol       Date:  1999-12       Impact factor: 4.335

Review 2.  Adverse drug reactions to systemic antifungals. Prevention and management.

Authors:  J R Perfect; M H Lindsay; R H Drew
Journal:  Drug Saf       Date:  1992 Sep-Oct       Impact factor: 5.606

3.  Antifungal activity of Lactobacillus against Microsporum canis, Microsporum gypseum and Epidermophyton floccosum.

Authors:  Jiahui Guo; Brid Brosnan; Ambrose Furey; Elke Arendt; Padraigin Murphy; Aidan Coffey
Journal:  Bioeng Bugs       Date:  2012-03-01

Review 4.  Effects of the antifungal agents on oxidative drug metabolism: clinical relevance.

Authors:  K Venkatakrishnan; L L von Moltke; D J Greenblatt
Journal:  Clin Pharmacokinet       Date:  2000-02       Impact factor: 6.447

5.  Rhabdomyolysis in a patient receiving atorvastatin and fluconazole.

Authors:  Juhani Kahri; Miia Valkonen; Tom Bäcklund; Matti Vuoristo; Kari T Kivistö
Journal:  Eur J Clin Pharmacol       Date:  2004-12-30       Impact factor: 2.953

Review 6.  Onychomycosis. Going for cure.

Authors:  A K Gupta; N H Shear
Journal:  Can Fam Physician       Date:  1997-02       Impact factor: 3.275

Review 7.  Clinically significant drug interactions with cyclosporin. An update.

Authors:  C Campana; M B Regazzi; I Buggia; M Molinaro
Journal:  Clin Pharmacokinet       Date:  1996-02       Impact factor: 6.447

Review 8.  Fluconazole. An update of its antimicrobial activity, pharmacokinetic properties, and therapeutic use in vaginal candidiasis.

Authors:  C M Perry; R Whittington; D McTavish
Journal:  Drugs       Date:  1995-06       Impact factor: 9.546

9.  The novel azole R126638 is a selective inhibitor of ergosterol synthesis in Candida albicans, Trichophyton spp., and Microsporum canis.

Authors:  Hugo Vanden Bossche; Jannie Ausma; Hilde Bohets; Karen Vermuyten; Gustaaf Willemsens; Patrick Marichal; Lieven Meerpoel; Frank Odds; Marcel Borgers
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

10.  Effects of cytochrome p450 inhibitors on itraconazole and fluconazole induced cytotoxicity in hepatocytes.

Authors:  Nhareet Somchit; Chong Sock Ngee; Azhar Yaakob; Zuraini Ahmad; Zainul Amiruddin Zakaria
Journal:  J Toxicol       Date:  2009-07-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.